Treventis founders publish new computational methodology for brain drug design

BBB score figure

Treventis founders Dr. Donald Weaver, Mark Reed, and Christopher Barden have supervised research at Toronto hospital UHN into new methods for predicting blood-brain permeability.  This research has culminated in two recent papers.

Two papers by primary author and UHN postdoctoral associate Mayuri Gupta discuss the Blood-Brain Barrier (BBB) and the Brain Exposure Efficiency (BEE) scoring systems.  BBB, building on the success of “CNSMPO” approaches in brain drug design, has already been cited nearly 5,000 times and is emerging as a new standard metric for predicting blood-brain barrier penetrance.  BEE works to extend the applicability of computational methods to looking at multiple efflux transporters in the brain.

Share this page

#pf-body .pf-caption img.blockImage { margin: 0!important; float: none; } #pf-body a.elementor-icon, #pf-body a.skip-link{display:none!important;} /*#pf-content {max-width:100%!important}*/ #pf-content img.mediumImage, #pf-content figure.mediumImage { margin-left: auto!important; margin-right: auto!important; clear: both!important; float: none!important; display: block!important; }